Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in La Roche sur Yon – page 5

224 clinical trials in La Roche sur Yon, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
La Roche sur Yon at a glance
224
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

224 trials in La Roche sur Yon

Open in trial search

Rectal cancer+1

Recruiting

Study on Encorafenib and Cetuximab for Patients with BRAF V600E-Mutated Localized Colon or Upper Rectum Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Plasma cell myeloma

Recruiting

Study on Dexamethasone for Patients with Advanced Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Recruiting

Study of Repotrectinib for Frail or Elderly Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Rearrangement

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer

Rectal cancer+2

Recruiting

Study of Dostarlimab Combined with Short Course Radiotherapy for Locally Advanced Rectal Cancer Patients with Microsatellite Instability

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Polycythaemia vera+4

Recruiting

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Squamous cell carcinoma of lung

Recruiting

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Multiple sclerosis

Recruiting

Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Colorectal cancer metastatic+2

Recruiting

Study on the Effects of Atezolizumab, Bevacizumab, Oxaliplatin, and Capecitabine in Patients with Colorectal Cancer and Liver Metastasis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Staphylococcal infection

Recruiting

Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Assistance Publique Hopitaux De Paris

B-cell lymphoma+1

Recruiting

Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Valemetostat Tosilate
  • Sponsor:LYSARC

Rheumatoid arthritis

Recruiting

Study on Adjusting Adalimumab Dosage for Patients with Rheumatoid Arthritis in Remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in La Roche sur Yon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, breast cancer, and colorectal cancer treatments. Studies include evaluation of new therapeutic combinations and maintenance strategies.

  • Advanced breast cancer therapies
  • Multiple myeloma treatments
  • Colorectal cancer interventions

Investigations include novel drug combinations and targeted therapies for various cancer types.

02 Immunology & Inflammatory Conditions

Research focusing on treatments for Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Studies evaluate new therapeutic approaches for inflammatory conditions.

  • Inflammatory bowel diseases
  • Autoimmune disorders
  • Novel immunotherapy approaches

Trials aim to improve treatment outcomes for patients with chronic inflammatory conditions.

03 Cardiovascular & Metabolic Research

Studies examining treatments for heart failure prevention, chronic kidney disease, and related cardiovascular conditions. Focus on innovative therapeutic combinations.

  • Heart failure prevention
  • Kidney disease management
  • Cardiovascular outcomes

Investigation of new approaches to prevent and treat cardiovascular complications.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.